Health Condition 1: null- Maternal Anemia
Conditions
Interventions
Intervention1: Drugs for Treating H.pylori treatment,Treatment of Anemia: Clarithromycin 250mg bid, 7 days, Lansoprazole 30mg bid,7days, Tinidazole 500mg bid 7 days, Ferrous Sulphate 150mg (50mg eleme
Sponsors
Unviesity of Alabama at Birmingham USA
Eligibility
Inclusion criteria
Inclusion criteria: 1.Women of childbearing age (18 to 35years); 2.Blood Hemoglobin (Hb) ï?£115g/L; 3.BMI 4.Willing to participate in the study; 5.Stays within reasonable distance from the study site; for follow â??up; 6.Positive for H. pylori antibody by rapid diagnostic test; 7.Positive for H. pylori â??Cag Aâ?? status.
Exclusion criteria
Exclusion criteria: 1.Acute and chronic diseases such as aplastic anemia, thalassamia, or hemolytic anemia; 2.Treatment with antibiotics during past one month; 3.Blood transfusion or blood donation within the last 4 months; 4.Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measure is the rise in blood hemoglobin level following eradication of H. pylori infection and 3 months treatment with iron-folate (FeFA) supplementation compared to the group who received FeFA supplement daily for 3 months (without eradication of H. pylori) in anemic and undernourished women of child bearing age. The two groups will be compared for the increment of hemoglobin from base line to end of supplementation.Timepoint: 0 to 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures include blood levels of total iron, ferritin, total iron binding capacity (TIBC) and they will be compared between the two groups after iron-folate supplementation.Timepoint: 0 to 3 months | — |
Countries
India
Contacts
Public ContactDr Dilip Mahalanabis
Society for Applied Studies
Outcome results
None listed